BCMA-Targeted Therapies in Multiple Myeloma: What the Pharmacist Needs...

Actions Panel

BCMA-Targeted Therapies in Multiple Myeloma: What the Pharmacist Needs...

Attend in-person or virtually!

When and where

Date and time

Location

Gaylord National Resort and Convention Center 201 Waterfront Street National Harbor Ballroom 10 National Harbor, MD 20745

Map and directions

How to get there

About this event

Activity Chair

Ryan Haumschild, PharmD, MS, MBA

Director of Pharmacy

Emory Healthcare

Winship Cancer Institute

Atlanta, GA

Faculty

Craig Freyer, PharmD, BCOP

Clinical Pharmacy Specialist – Hematology/Oncology, Stem Cell Transplant, and Cellular Therapy

Penn Medicine at The Pavilion of Hospital of the University of Pennsylvania

Philadelphia, PA

Noopur Raje, MD

Director, Center for Multiple Myeloma

Massachusetts General Hospital

Professor of Medicine

Harvard Medical School

Boston, MA

Saad Usmani, MD, MBA, FACP

Chief of Myeloma Service

Member, Memorial Sloan Kettering Cancer Center

Attending Physician, Myeloma, Cellular Therapy and Adult BMT

New York, NY

Overview

Although the median overall survival rate for patients with multiple myeloma (MM) has nearly doubled during the last 2 decades, MM remains incurable, and a majority of patients develop relapsed disease. The prognosis is poor among these patients, with a median overall survival of just over 1 year after 3 lines of therapy. Although improvements in diagnosis, risk stratification, and treatment continue—with multiple agents now available from various drug classes—additional novel agents with improved efficacy and safety are still needed, particularly in the relapsed or refractory setting. Several therapies have recently been approved that target B-cell maturation antigen (BCMA), a transmembrane protein expressed by malignant plasma cells that is involved in plasma and B-cell survival, B-cell maturation and growth, and activation of regulatory T cells. In this activity, expert clinicians will review the current treatment guidelines and the most recent clinical data supporting the use of BCMA-targeted for relapsed/refractory MM, define the disease and clinical characteristics of patients for whom BCMA-targeted therapy is appropriate, and describe the optimal multidisciplinary care coordination strategies for the management of treatment-emergent adverse events in patients receiving BCMA-targeted therapies.

Agenda

6:00 PM

Registration and Dinner

6:30 PM

Introduction and Pretest

Ryan Haumschild, PharmD, MS, MBA

6:35 PM

Therapeutic Options for Relapsed/Refractory Multiple Myeloma

Noopur Raje, MD

6:50 PM

Targeting BCMA in Relapsed/Refractory Disease

Saad Usmani, MD, MBA, FACP

7:05 PM

Safety Considerations Associated With BCMA-Targeted Therapies

Craig Freyer, PharmD, BCOP

7:25 PM

Clinical Cases

Ryan Haumschild, PharmD, MS, MBA

7:45 PM

Posttest and Question & Answer

8:00 PM

Conclusion

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Outline current guideline recommendations for the treatment of relapsed/refractory MM.
  • Review the patient, disease, and treatment characteristics that may make patients likely to benefit from BCMA-targeted therapies.
  • Assess the latest clinical efficacy data and safety profiles for recently approved BCMA-targeted therapies for patients with relapsed/refractory MM.
  • Define multidisciplinary care coordination strategies for the recognition and management of adverse events in patients receiving BCMA-targeted therapies.

Target Audience

The intended audience for this activity is managed care pharmacists, oncology pharmacists, and other health care professionals involved in the management of patients with MM.

BCMA-Targeted Therapies in Multiple Myeloma: What the Pharmacist Needs... image